After anti-HER2 treatment, in tumours exhibiting HER2 amplification, there would be a downregulation in the release of cytokines, including CCL2, CCL21, VEGF, and CXCL1, which leads to an amelioration of the immunosuppressive factors within the tumour microenvironment20. This evidence concerns the gene CCL2 and neoplasm.